UNSPSC 51392501: Rimiterol

This classification denotes a beta-adrenergic agonist with the molecular formula C22H32N2O6H2O4S; a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U851S9102C; chemically known as 4;4-(hexane-1;6-diylbis(iminio(1-hydroxyethylene)))dipyrocatecholsulphate but generally known as hexoprenaline sulfate; which bears US National Institutes of Health Compound Identifier 36094 European Medicines Agency schedules Hexoprenaline sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02516MIG Most nations schedule rimiterol under HS 29333999 and SITC 51574.

UNSPSC 51392501 Rimiterol, a Commodity code, nominally refers to a specific pharmaceutical product, but the recent state and local opportunities tagged to this code show minimal direct relevance to rimiterol itself. Instead, the code appears in solicitations for naloxone procurement and prescription-program infrastructure, neither of which align with rimiterol's therapeutic scope. The mismatch suggests that state and local procurement offices are using this code as a catch-all for pharmaceutical and pharmacy-related purchases rather than for rimiterol specifically. The opportunities posted under the code reflect broader health and human services purchasing — notably naloxone and drug-deactivation systems for community health support, and exploratory contracting for direct-to-manufacturer prescription programs — indicating that the code's practical application in state and local procurement diverges significantly from its nominal definition.

Activity under this code is limited to two recent opportunities: Seminole County, Florida issued an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, requiring quarterly deliveries to the Seminole County Community Health Building and electronic bid submission through the county's e-Procurement Portal; and the Texas Health and Human Services Commission posted an RFI on March 27, 2026 (response due April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting with pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The geographic spread is minimal, touching only Florida and Texas in recent months. Given the sparse activity and the apparent mismatch between code assignment and actual scope of work, this code shows little current traction for vendors focused on rimiterol or traditional pharmaceutical commodity procurement.